Friday, January 21, 2022
wellness India Expo
Home Tags COVAXIN

Tag: COVAXIN

COVAXIN (BBV152) booster shown to neutralize both Omicron & Delta variants...

100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant

COVAXIN booster dose study shows promising results

The phase 2, double-blind, randomised controlled COVAXIN trial demonstrated long-term safety with no serious adverse events

First-ever study in India claims Covid-19 vaccine cocktails are safe

Mix and match of different vaccines is safe and elicits robust antibody response, revealed the study conducted by AIG Hospitals The first pilot study from India analyzing COVAXIN – COVISHEILD mixed doses

COVAXIN for children: Study demonstrates robust safety & immunogenicity in 2-18...

Whole-Virion inactivated SARS-CoV-2 Vaccine (BBV152) has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults......................

Covaxin P3 data published in Lancet, overall 77.8% efficacy confirmed

This first publication of the data shows COVAXIN has 93.4% efficacy against severe COVID-19 disease, 77.8% overall efficacy, 63.6% efficacy against asymptomatic disease and 65.2% efficacy against the Delta variant in the Phase 3 clinical trial of 25,798 participants..........................

Bharat Biotech’s partner seeks Covaxin nod in US for children between...

Covaxin, developed in India by Bharat Biotech, gained emergency approval from the World Health Organization (WHO) and has already been cleared for use in 17 countries......................

Covaxin gets nod for kids aged 2-18 years

The Subject Expert Committee (SEC) has given a nod for use of Covaxin for children in the 2-18 years age group

Covid Vaccine Cocktail: Is it OK to get 2 doses from...

It is becoming more likely that India may start giving Covid vaccine cocktails to its citizens, opines Dr Haryax Pathak who bats for its inclusion in the vaccination drive..................................

Bharat Biotech issues statement to ward off fake news on Covaxin

The company has stated that the fake news and false and misleading narratives result in unintended consequences of creating panic in a large number of people, resulting in vaccine hesitancy.......................

Phase-3 trial results show COVAXIN is 77.8% effective against symptomatic COVID-19

Efficacy analysis demonstrates COVAXIN to be 93.4% effective against severe symptomatic COVID-19. Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant..................................